Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone vs Dexamethasone in Childhood Lymphoblastic Lymphoma (EURO-LB02)
NCT00275106Phase 3Terminated
- Sponsor
- Children's Cancer and Leukaemia Group
- Start
- Sep 2004
- Primary completion
- Dec 2009
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in lymphoblastic lymphoma (LL) (2 arms), sponsored by Children's Cancer and Leukaemia Group. Primary endpoints: Event-Free Survival and Safety of Maintenance Treatment at 24 months. Started Sep 2004; status: terminated.
02
Drugs
dexamethasone
03
Conditions
lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00275106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275106.